Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

T Cell Therapy's Most Valuable IP Placed On Open Market


News provided by

TCellTherapy.com

May 03, 2016, 02:46 ET

Share this article

Share toX

Share this article

Share toX

PHOENIX and FRIBOURG, Switzerland, May 3, 2016 /PRNewswire/ -- In the midst of the most promising advance in the successful treatment, some even say, "cure," for cancer, perhaps the most elusive and frightening of all the world's widely-spread and often terminal diseases, $10's of billions are presently being invested by companies worldwide, in the development and forthcoming commercialization of a relatively new, yet recently proven, modality for successfully treating and frequently annihilating, various forms of cancer – T Cell Therapy AKA T Cell Immunotherapy, and its various sub-types, including Cellular Immunotherapy, Adoptive Immunotherapy, etc.

T Cell Immunotherapy .COM Domain Names Now Offered For Sale at www.TCellTherapy.com
T Cell Immunotherapy .COM Domain Names Now Offered For Sale at www.TCellTherapy.com

To assist the aforementioned corporate and biotechnology organizations in the forthcoming marketing, commercialization and sales of their various T Cell Therapy and T Cell Immunotherapy products to tackle cancer, 19-year veteran .COM Domain Name Broker, Neal Sutz, is today offering the world's most important, valuable and effective pieces of Internet Real Estate for this industry to the worldwide T Cell Therapy and T Cell Immunotherapy marketplace, via his project website – www.TCellTherapy.com.

Industry analysts and experts indicate in their analytics and subsequent industry growth and projected revenue reports that this "new, safer and more effective" treatment for various types of cancer is expected to attain a minimum of $30 Billion in annual revenues in the forthcoming five years, and then increasing at a rate of at least 100% for each subsequent year thereafter.  This growth is said to have been determined via intensive studies of the methodologies used in the creation of the reengineering the efficacy of T Cells to treat cancer in the most effective and apparently safest methods ever developed.  As the efficacy of T Cell Therapy becomes more accelerated and the efforts towards marketing and commercialization of the various T Cell Immunotherapy modalities (sub-types) become more aggressive and successful by those organizations wishing to achieve 1st place in the race to lead this burgeoning industry, the largest percentages of this projected industry market revenue is sure to be won by the companies most willing to invest in the appropriate and directly-targeted marketing methodologies and pieces of marketing-related Intellectual Property.

With major players such as Sean Parker, of Facebook and Napster fame, entering the T Cell Immunotherapy space, as well as every major and nearly every minor pharmaceutical, biotechnology, cancer research and treatment facility in the world diligently striving to be this infant industry's sales leader, it made unquestionably clear sense to Domain Broker, Neal Sutz, to acquire and centralize the largest collection ever assembled of T Cell Immunotherapy .COM domain names and offer them for sale in the open market via a worldwide PR campaign previously unmatched in the URL aftermarket sale space.

Sutz, via his project website at www.TCellTherapy.com, is presenting his URLS, without question the most important, valuable and pertinent .COM domain names ever offered to the open market, in an industry so groundbreaking so as to redefine the very way in which the world's most deadly disease, cancer, is approached with which to do battle. 

Sutz's industry-wide .COM domain name offering is based upon Big Pharma's 20-year pattern of spending millions of dollars of their annual marketing budgets on the acquisition and utilization of "generic" .COM domain names such as Depression.com, ProstateCancer.com, ADHD.com, CancerTreatment.com, etc. 

That fact, in addition to the $10's of millions that the aforementioned pharmaceutical and cancer treatment giants each spend annually to secure, strengthen and drive into the mind of the consumer the branded and trademarked names of their products, makes Sutz's T Cell Immunotherapy .COM domain names the most valuable and important marketing-related pieces of IP which any company, from Novartis to GSK to Celgene and the many other industry players, could possibly acquire and then utilize to dominate this new, highly-competitive marketplace.

Sutz is confident that the acquisition of any, if not all of his T Cell Therapy, et al. .COM domains, including but not limited to, TCellTherapy.com, TCellImmunotherapy.com, CellularImmunotherapy.com, ImmunotherapyVaccine.com, will be, by the right organization(s), the, "...most intelligent, powerful and effective IP acquisition that any of them could implement when determining their corporate strategies as to how best dominate the commercialization and profiting aspect of the world's most promising treatment avenue to tackle and lead the world's race to commercialize and profit from cancer therapy, unlike anything that the last 100 years have ever seen."

Sutz continued, "Based upon previous industry .COM domain name sales, in the mid-seven to low-eight figure range, such as Porn.com for $9.5M in an industry 2/3rds smaller than the projected T Cell Therapy industry revenue figures of at least $30 Billion in the first official year, I anticipate the sale of the URLS I have collected and am making available to companies which wish to have the most powerful tools to market their T Cell Therapy, et al. products, will join the ranks of the domain name resale industry's largest sales ever."

Sutz continued, "There is no other property currently on the open market that even compares to what I am offering.  After 19 years in this industry, having sold effective and valuable .COM domain names to over a dozen Big Pharma companies, and thousands of domain names to hundreds of other small, medium and large corporations in numerous other industries, I feel my skill set in the acquisition and offering of powerful, generic .COM domain names, especially a veritable monopoly as I have put together and am offering in this soon-to-be multi-billion dollar industry, has finally been put to the ultimate test in how to have acquired and how to properly promote the sale of, what are unquestionably the most valuable domain names currently on the market in the pharmaceutical and biotechnology industries."

Sutz's Immunotherapy Domain Name Auction can be reviewed and is being presented at the project URL, www.TCellTherapy.com.  All contact information with which to make an inquiry or bid can be found on the project's Home Page.

Photo - http://photos.prnewswire.com/prnh/20160503/363087

SOURCE TCellTherapy.com

Related Links

http://www.TCellTherapy.com

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.